1 |
Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
DOI
|
2 |
Daopin S, Piez KA, Ogawa Y, et al (1992). Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. Science, 257, 369-73.
DOI
|
3 |
Greenlee RT, Murray T, Bolden S, et al (2000). Cancer statistics, 2000. CA Cancer J Clin, 50, 7-33.
DOI
ScienceOn
|
4 |
Hallberg B, Palmer RH (2010). Crizotinib--latest champion in the cancer wars? N Engl J Med, 363, 1760-2.
DOI
ScienceOn
|
5 |
Janku F, Stewart DJ, Kurzrock R (2010). Targeted therapy in non-small-cell lung cancer -- is it becoming a reality? Nat Rev Clin Oncol, 7, 401-14.
DOI
|
6 |
Kwak EL, Bang YJ, Camidge DR, et al (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 363, 1693-703.
DOI
|
7 |
McDermott U, Iafrate AJ, Gray NS, et al (2008). Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res, 68, 3389-95.
DOI
|
8 |
Lam WK, White NW, Chan-Yeung MM (2004). Lung cancer epidemiology and risk factors in Asia and Africa. Int J Tuberc Lung Dis, 8, 1045-57.
|
9 |
Lengauer T, Rarey M (1996). Computational methods for biomolecular docking. Curr Opin Struct Biol, 6, 402-6.
DOI
|
10 |
Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
DOI
ScienceOn
|
11 |
Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
DOI
ScienceOn
|
12 |
Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11.
DOI
ScienceOn
|
13 |
Qin BY, Lam SS, Correia JJ, et al (2002). Smad3 allostery links TGF-beta receptor kinase activation to transcriptional control. Genes Dev, 16, 1950-63.
DOI
ScienceOn
|
14 |
Taylor RD, Jewsbury PJ, Essex JW (2002). A review of protein-small molecule docking methods. J Comput Aided Mol Des, 16, 151-66.
DOI
|
15 |
Schmierer B, Hill CS (2007). TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol, 8, 970-82.
DOI
|
16 |
Subramanian J, Govindan R (2008). Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol, 9, 676-82.
DOI
|
17 |
Sukits SF, Lin LL, Hsu S, et al (2001). Solution structure of the tumor necrosis factor receptor-1 death domain. J Mol Biol, 310, 895-906.
DOI
|
18 |
Wang Z, Canagarajah BJ, Boehm JC, et al (1998). Structural basis of inhibitor selectivity in MAP kinases. Structure, 6, 1117-28.
DOI
|
19 |
Xu ZY, Blot WJ, Xiao HP, et al (1989). Smoking, air pollution and the high rates of lung cancer in Shenyang, China. J Natl Cancer Inst, 81, 1800-6.
DOI
|
20 |
Yang JM (2004). Development and evaluation of a generic evolutionary method for protein-ligand docking. J Comput Chem, 25, 843-57.
DOI
|
21 |
Zhou S, Buckhaults P, Zawel L, et al (1998). Targeted deletion of Smad4 shows it is required for transforming growth factor beta and activin signaling in colorectal cancer cells. Proc Natl Acad Sci USA, 95, 2412-6.
DOI
|
22 |
Yang JM, Chen CC (2004). GEMDOCK: a generic evolutionary method for molecular docking. Proteins, 55, 288-304.
DOI
|